One dose, no titration

GEMTESA is a beta-3 agonist that offers
your patients1:

  • Calendar icon. GEMTESA® is a once-daily 75-mg dose, to be taken with or without food and swallowed whole with a glass of water.

    Once-daily 75-mg dose with no titration to be taken with or without food and swallowed whole with
    a glass of water1

  • Pill crusher icon. In adults, GEMTESA® tablets may be crushed, mixed with a tablespoon (~15 ml) of applesauce and taken immediately with a glass of water.

    Crushability In adults, GEMTESA tablets may be crushed, mixed with a tablespoon (~15 mL) of applesauce and taken immediately with a glass of water1

Patient ready to take a pill. GEMTESA® is a beta-3 agonist that is one dose.
GEMTESA® pill bottle. Request samples for your appropriate patients.

Interested in prescribing GEMTESA? Request samples for your patients

Click below to request samples or request a live or virtual
visit with a GEMTESA representative.

Request samples

Request a rep

You and your patients can work together to help ensure they get the OAB treatment you have chosen

Healthcare professional Consider the following, where appropriate,
for patients who are having trouble filling prescriptions:

  • DAW (dispense as written)*
  • Medically necessary
  • Brand only

*Follow your state's required language or special instructions.

Patient or caregiver May consider the following to communicate with the pharmacy:

  • Request no substitutions before the medication is dispensed
  • Verify they have received GEMTESA
  • Discuss options with the pharmacists (if they have not received GEMTESA before leaving the pharmacy)
Sample prescription.

But wait, there’s more!

GEMTESA demonstrated statistically significant reduction of all 3 key OAB symptoms* vs placebo at 12 weeks— including urgency1,2†

See how GEMTESA may help your
patients in long-term care with OAB
Learn more
Patient calmly listening. Learn how to order GEMTESA® for your long-term care facility.

*The 3 key symptoms of OAB are urgency, micturition frequency, and urge urinary incontinence (UUI)/leakage.2

The efficacy of GEMTESA was evaluated in a 12-week, double-blind, randomized, placebo- and active-controlled trial in patients with OAB (UUI, urgency, and urinary frequency). For study entry, patients had to have symptoms of OAB for at least 3 months with an average of 8 or more micturitions per day and at least 1 UUI per day, or an average of 8 or more micturitions per day and an average of at least 3 urgency episodes per day. A total of 1515 patients received at least 1 daily dose of placebo (n=540), GEMTESA 75 mg (n=545), or an active-control treatment (n=430). The majority of patients were Caucasian (78%) and female (85%) with a mean age of 60 (range 18 to 93) years.1

 

References: 1. GEMTESA. Prescribing information. Urovant Sciences GmbH; 2020. Accessed January 4, 2021. https://gemtesa.com/sites/default/files/gemtesa-prescribing-information.pdf 2. Edmondson SD, Zhu C, Kar NF, et al. Discovery of vibegron: a potent and selective β3 adrenergic receptor agonist for the treatment of overactive bladder. J Med Chem. 2016;59(2):609-623. doi:10.1021/acs.jmedchem.5b01372